CJM 112

Drug Profile

CJM 112

Alternative Names: CJM112

Latest Information Update: 17 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne; Asthma; Hidradenitis suppurativa
  • Phase I/II Plaque psoriasis
  • Phase I Multiple myeloma; Solid tumours
  • Preclinical Multiple sclerosis

Most Recent Events

  • 01 Aug 2018 Novartis completes a phase II trial in Acne (In adolescents, In adults) in Netherlands, Germany, USA (SC) (NCT02998671)
  • 06 Nov 2017 Phase-II clinical trials in Asthma (Adjunctive treatment) in Slovakia, Denmark, Germany, Belgium, USA (SC) (NCT03299686) (EudraCT2017-000205-21)
  • 03 Oct 2017 Novartis Pharmaceuticals plans a phase II trial for moderate to severe Asthma (Adjunctive treatment, In adults) (NCT03299686)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top